Current Opinion in Infectious Diseases最新文献

Clinical and genetic risk factors for apolipoprotein L1-mediated chronic kidney disease in people of African ancestry with HIV. 非洲血统HIV感染者载脂蛋白l1介导的慢性肾病的临床和遗传危险因素

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-12 DOI: 10.1097/QCO.0000000000001253

Frank A Post, Dami Collier, Cheryl A Winkler

{"title":"Clinical and genetic risk factors for apolipoprotein L1-mediated chronic kidney disease in people of African ancestry with HIV.","authors":"Frank A Post, Dami Collier, Cheryl A Winkler","doi":"10.1097/QCO.0000000000001253","DOIUrl":"https://doi.org/10.1097/QCO.0000000000001253","url":null,"abstract":"Purpose of review: To summarize current understanding of the epidemiology, pathogenesis and management of HIV-Associated Nephropathy (HIVAN) and other forms of Apolipoprotein L1 (APOL1)-mediated chronic kidney disease (CKD) in people of African ancestry with HIV.Recent findings: The G1 and G2 variants of the APOL1 gene, which have emerged in trypanosomiasis-endemic areas of Africa, predispose to HIV-associated nephropathy (HIVAN) and other forms of CKD. The risk of APOL1-mediated CKD is attenuated with HIV control and carriage of the p.N264K genetic variant. Several treatments targeting the APOL1 gene and the transmembrane ion channel encoded by the APOL1 gene are being evaluated in clinical trials; early findings indicate they achieve rapid and marked reductions in proteinuria in those with established APOL1-mediated CKD.Summary: Genetic variants of APOL1 are causally implicated in HIVAN and other forms of severe CKD in populations of African ancestry with HIV. Genetic, epigenetic and environmental factors influence the risk of developing APOL1-mediated CKD, and emerging APOL1-directed therapies offer the prospect of clinical remission to those with established APOL1-mediated CKD.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reducing antibiotic burden in gram-negative bacteraemia: duration optimization and early oral transition. 减少革兰氏阴性菌血症的抗生素负担：持续时间优化和早期口服过渡。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-12 DOI: 10.1097/QCO.0000000000001242

Renato Pascale, Matteo Montironi, Maddalena Giannella

{"title":"Reducing antibiotic burden in gram-negative bacteraemia: duration optimization and early oral transition.","authors":"Renato Pascale, Matteo Montironi, Maddalena Giannella","doi":"10.1097/QCO.0000000000001242","DOIUrl":"https://doi.org/10.1097/QCO.0000000000001242","url":null,"abstract":"Purpose of review: Gram-negative bloodstream infections have traditionally been managed with prolonged and intravenous antibiotic therapy. This review aims to summarize the evidence supporting strategies to reduce antibiotic burden through shorter treatment durations and/or oral step-down therapy.Recent findings: Recent randomized controlled trials, target trial emulations, and large observational studies demonstrate that in patients with uncomplicated Gram-negative bloodstream infections an early oral step-down therapy and/or reduced antibiotic courses achieve clinical outcomes comparable to prolonged intravenous therapy and longer treatment durations. Fluoroquinolones and trimethoprim-sulfamethoxazole remain the preferred oral agents because of their high bioavailability. Appropriately dosed oral β-lactams appear to provide comparable outcomes, highlighting the importance of exposure optimization rather than antibiotic class alone. The evidence is expanding also for special populations, but important knowledge gaps remain for patients with severe immunosuppression and multidrug-resistant pathogens.Summary: Current evidence supports reducing antibiotic exposure in selected patients with Gram-negative bloodstream infections by combining shorter treatment durations and early oral step-down therapy. Future studies should address remaining evidence gaps, particularly in frail patients.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening for multidrug-resistant organism: clinical benefit or unquestioned routine. 筛选多药耐药菌：临床获益或毫无疑问的常规。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-12 DOI: 10.1097/QCO.0000000000001248

Alex Soriano, Marta Ulldemolins, Cristina Pitart, Pedro Castro, Mateu Espasa, Josep Mensa

{"title":"Screening for multidrug-resistant organism: clinical benefit or unquestioned routine.","authors":"Alex Soriano, Marta Ulldemolins, Cristina Pitart, Pedro Castro, Mateu Espasa, Josep Mensa","doi":"10.1097/QCO.0000000000001248","DOIUrl":"https://doi.org/10.1097/QCO.0000000000001248","url":null,"abstract":"Purpose of review: Current strategies for multidrug-resistant organism (MDRO) screening are primarily intended to support infection prevention programs. However, accumulating evidence indicates that intestinal colonization also provides clinically relevant information for antimicrobial stewardship. This review examines the biological basis and clinical utility of mucosal screening for optimizing empirical antibiotic therapy and proposes a new conceptual framework linking intestinal pathobiont burden with endogenous bloodstream infection.Recent findings: Recent studies consistently show that the absence of MDRO carriage is associated with a very low risk of subsequent infection, supporting well tolerated antimicrobial de-escalation in patients with negative clinical cultures. Emerging evidence further indicates that prolonged exposure to antianaerobic antibiotics promotes expansion of intestinal pathobionts, whereas preservation or restoration of the gut microbiota limits this process. Experimental and clinical observations suggest that the abundance of pathobionts, rather than simple carriage status, determines the probability of bacterial translocation and invasive infection.Summary: We propose that physiological bacterial translocation from the intestinal microbiota is a common phenomenon and may represent one of the mechanisms of bloodstream infection in critically ill and immunocompromised patients. In this model, progression to invasive infection depends on intestinal pathobiont burden exceeding the capacity of host immune clearance. If validated, this concept would support a transition from qualitative MDRO screening to quantitative assessment of intestinal pathobiont burden to guide antimicrobial stewardship and targeted preventive strategies.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149172160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing KPC infections in daily practice: when BLBLIs are interchangeable - and when they are not. 在日常实践中管理KPC感染：什么时候blbli是可互换的——什么时候它们不是。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-09 DOI: 10.1097/QCO.0000000000001238

Vasiliki Rapti, Ilias Karaiskos, Garyfallia Poulakou

{"title":"Managing KPC infections in daily practice: when BLBLIs are interchangeable - and when they are not.","authors":"Vasiliki Rapti, Ilias Karaiskos, Garyfallia Poulakou","doi":"10.1097/QCO.0000000000001238","DOIUrl":"10.1097/QCO.0000000000001238","url":null,"abstract":"Purpose of review: Κlebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales infections are currently treatable with novel β-lactam-β-lactamase inhibitors (BLBLIs) combinations, but their optimal use in daily practice requires defining when ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MER-VAB), and imipenem-cilastatin-relebactam (IMI-REL) are clinically interchangeable and when treatment should be individualized.Recent findings: Contemporary surveillance and observational data support high activity of all three agents against confirmed KPC-producing Enterobacterales, providing a rationale for interchangeability in low-risk infections with source control and no recent BLBLI exposure. However, clinically relevant differences are increasingly recognized. CAZ-AVI resistance is most often linked to KPC variants, whereas reduced MER-VAB and IMI-REL susceptibility more frequently involves porin loss, reduced permeability, and increased β-lactamase expression. Pneumonia, high MICs, altered renal function, renal replacement therapy, prior BLBLI exposure, persistent colonization, immunocompromise, and delayed source control may narrow interchangeability.Summary: BLBLI with KPC activity interchangeability is clinically reasonable only in selected, microbiologically confirmed, low-risk scenarios. In complex infections, therapy should be guided according to resistance mechanism, infection site, pharmacokinetics/pharmacodynamics (PK/PD) parameters, and host factors.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe strongyloidiasis and Gram-negative bacterial superinfections: epidemiology, clinical implications, and therapeutic strategies. 严重圆线虫病和革兰氏阴性细菌重复感染：流行病学，临床意义和治疗策略。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-09 DOI: 10.1097/QCO.0000000000001249

Chiara Sepulcri, Antonio Vena, Matteo Bassetti

{"title":"Severe strongyloidiasis and Gram-negative bacterial superinfections: epidemiology, clinical implications, and therapeutic strategies.","authors":"Chiara Sepulcri, Antonio Vena, Matteo Bassetti","doi":"10.1097/QCO.0000000000001249","DOIUrl":"https://doi.org/10.1097/QCO.0000000000001249","url":null,"abstract":"Purpose of review: Strongyloidiasis is a neglected tropical disease affecting over 600 million people worldwide. Its severe forms carry a fatality rate exceeding 60%, yet death is rarely attributable to the parasite alone: the terminal event is often bacterial sepsis or meningitis of enteric origin. We review recent evidence on Gram-negative and other bacterial superinfections in severe strongyloidiasis, and their diagnostic and therapeutic implications.Recent findings: Cohort studies show that bacteraemia is the commonest complication of severe disease, affecting 38.3% of cases against 4.1% of uncomplicated infections, and is predominantly Gram-negative, with Klebsiella pneumoniae and Escherichia coli most often isolated; Gram-positive and polymicrobial infections also occur. Beyond corticosteroids, targeted immunosuppressants and transplantation are increasingly implicated. Recognition is difficult, as eosinophilia is frequently absent and serological tests, including recent rapid assays, perform poorly in immunocompromised patients. Diagnostic delay is associated with higher risk of sepsis and mortality. Emodepside and moxidectin show promise in chronic infection but remain untested in severe disease.Summary: Enteric Gram-negative bacteraemia or meningitis in an at-risk patient, particularly if recurrent or polymicrobial, should prompt parasitological investigation. As treatment of established disease is unproven, detecting and treating chronic infection before immunosuppression, including transplant donors and recipients, remains the intervention most likely to reduce mortality.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in Strongyloides screening, diagnostics, therapeutics, and management. 类圆线虫筛查、诊断、治疗和管理的最新进展。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-01 Epub Date: 2026-08-12 DOI: 10.1097/QCO.0000000000001217

Eva H Clark, Thomas B Nutman

{"title":"Recent advances in Strongyloides screening, diagnostics, therapeutics, and management.","authors":"Eva H Clark, Thomas B Nutman","doi":"10.1097/QCO.0000000000001217","DOIUrl":"10.1097/QCO.0000000000001217","url":null,"abstract":"Purpose of review: Strongyloidiasis affects an estimated 30-100 million people globally and can have life-threatening consequences in immunocompromised hosts, yet it remains underdiagnosed due to limited access and performance of available diagnostics. Novel assays and anthelmintics may reshape screening, diagnosis, treatment, and prevention for at-risk populations.Recent findings: Advances in molecular diagnostics coupled with robust stool extraction methods have supplanted traditional parasitologic methods in settings where nucleic acid amplification is feasible. Transition from standard immunoglobulin G (IgG)-based immunoassays to the new IgG- and IgG4-based rapid diagnostic tests using recombinant Strongyloides stercoralis nematode immunodominant E antigen (NIE) and/or S. stercoralis immunoreactive antigen (SsIR) has facilitated serologic screening at the point of care. The World Health Organization now conditionally recommends community-wide ivermectin mass drug administration in highly endemic settings. Regarding new treatment options, moxidectin is noninferior to ivermectin with 93-94% cure rates and a longer half-life, while emodepside shows 80-90% predicted cure rates in early trials and offers a mechanistically distinct option. Understanding of immunosuppressed populations at risk for hyperinfection has expanded, prompting updated screening recommendations.Summary: Serologic and molecular tools are improving screening and diagnosis, and moxidectin and emodepside may broaden treatment options, but data in severe disease and special populations remain limited. Priorities include harmonized screening algorithms and prospective studies in high-risk groups.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"422-428"},"PeriodicalIF":4.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148720602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving paradigms in pediatric osteomyelitis: modern insights into an old disease. 儿童骨髓炎的演变范式：对一种古老疾病的现代见解。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-01 Epub Date: 2026-08-12 DOI: 10.1097/QCO.0000000000001231

Jesús Saavedra-Lozano, Marta Agüera, Eneritz Velasco-Arnaiz

{"title":"Evolving paradigms in pediatric osteomyelitis: modern insights into an old disease.","authors":"Jesús Saavedra-Lozano, Marta Agüera, Eneritz Velasco-Arnaiz","doi":"10.1097/QCO.0000000000001231","DOIUrl":"10.1097/QCO.0000000000001231","url":null,"abstract":"Purpose of review: Acute hematogenous osteomyelitis (AHO) remains a potentially devastating infection in children, in which delayed diagnosis or inadequate therapy can result in significant long-term sequelae. This review provides an update of the epidemiology, diagnosis and management of pediatric AHO, with particular emphasis on emerging diagnostic tools and evolving therapeutic strategies aimed at preventing complications.Recent findings: Improved recognition by clinical and laboratory algorithms of age-specific pathogens, like Kingella kingae in young children or highly virulent organisms including methicillin-resistant Staphylococcus aureus (MRSA), may allow for individualized therapy. Novel molecular techniques, such as metagenomic next-generation sequencing (mNGS), offer the potential for broader and faster microbiological diagnosis. Multidisciplinary protocols that integrate early MRI may enhance anatomic delineation of infection and lead to faster detection of complications. Antibiotic stewardship programs based on local epidemiology support optimized empiric and targeted therapy, while early transition to oral antibiotics has been shown to improve quality of life and reduce healthcare resource utilization without compromising clinical outcomes.Summary: Although AHO continues to pose diagnostic and therapeutic challenges, its management is shifting toward individualized, evidence-based care driven by advances in diagnostics, risk stratification and antimicrobial stewardship. Future research should focus on developing and validating multidisciplinary protocols to further improve the accuracy of diagnosis.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"467-479"},"PeriodicalIF":4.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148720848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review into the recent advances in the world of amoebiasis. 阿米巴病的最新研究进展综述。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-01 Epub Date: 2026-08-26 DOI: 10.1097/QCO.0000000000001236

Louis Egerton, Gauri Godbole

{"title":"A review into the recent advances in the world of amoebiasis.","authors":"Louis Egerton, Gauri Godbole","doi":"10.1097/QCO.0000000000001236","DOIUrl":"10.1097/QCO.0000000000001236","url":null,"abstract":"Purpose of review: Amoebiasis is a parasitic infection caused by Entamoeba histolytica , affecting 10% of the global population. It is a well recognized cause of morbidity and mortality in low-middle-income countries where it is endemic. However, with increased migration and global travel, amoebiasis is now more common in high-income countries, although diagnosis is often delayed or even missed due to lack of awareness of the latest epidemiology and optimal diagnostic testing. This review discusses the evolving prevalence, and the current international guidelines for the investigation and treatment of amoebiasis, focusing on recent advances.Recent findings: The recent literature shows that the primary investigations for amoebiasis remain the same, though newer modalities such as artificial intelligence-powered microscopy and metagenomics have been developed recently, which aids the accuracy and speed of diagnosis. Treatment remains the same, though current research has found potential new drugs and drug targets which show promise.Summary: This review reinforces the importance of early clinical suspicion, diagnosis and treatment for amoebiasis. What was once a disease only seen in endemic countries or travel-associated imported cases is now more common and must not be missed.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"438-443"},"PeriodicalIF":4.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in typhoidal and non-typhoidal Salmonella vaccines. 伤寒和非伤寒沙门氏菌疫苗的最新进展。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-01 Epub Date: 2026-08-05 DOI: 10.1097/QCO.0000000000001230

Michael Blank, Anna Rydlova, Malick M Gibani

{"title":"Recent developments in typhoidal and non-typhoidal Salmonella vaccines.","authors":"Michael Blank, Anna Rydlova, Malick M Gibani","doi":"10.1097/QCO.0000000000001230","DOIUrl":"10.1097/QCO.0000000000001230","url":null,"abstract":"Purpose of review: Typhoidal and invasive non-typhoidal Salmonella (iNTS) serovars remain leading causes of bloodstream infection, mortality and morbidity, particularly in South Asia and sub-Saharan Africa. The rising burden of antimicrobial resistance has strengthened the case for vaccination as a control strategy. This review summarises recent advances in Salmonella vaccine development, highlighting progress, remaining challenges and future directions.Recent findings: The introduction of typhoid conjugate vaccine (TCV) programmes across some endemic countries represents a major public health milestone. Important questions remain, however. These include the durability of protection, optimal booster strategies and performance in diverse epidemiological settings. Vaccine development for S. Paratyphi A and iNTS has also accelerated, with candidates including conjugate, outer membrane vesicle/GMMA and live-attenuated, platforms advancing through preclinical and early clinical evaluation. Multivalent vaccine strategies have attracted growing interest. However, the divergent epidemiology of typhoidal and non-typhoidal disease, including differences in age-specific risk and geographic distribution, raises important questions about whether a single combination product is suitable for all settings.Summary: The Salmonella vaccine landscape is evolving rapidly from a focus on typhoid alone toward broader protection against multiple clinically important serovars. Although recent progress is encouraging, important scientific, regulatory, and implementation challenges remain. The practical case for integrated Salmonella vaccine strategies will depend on careful matching of vaccine composition to the differing epidemiology, age-specific risks, and delivery contexts of typhoidal and nontyphoidal disease.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"450-457"},"PeriodicalIF":4.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13566389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dengue and chikungunya vaccines past, present and future: implications for travelers. 登革热和基孔肯雅热疫苗的过去、现在和未来：对旅行者的影响。

IF 4.5 3区医学

Current Opinion in Infectious Diseases Pub Date : 2026-10-01 Epub Date: 2026-06-10 DOI: 10.1097/QCO.0000000000001211

Francesca F Norman, Sarah L McGuinness, Lin H Chen

{"title":"Dengue and chikungunya vaccines past, present and future: implications for travelers.","authors":"Francesca F Norman, Sarah L McGuinness, Lin H Chen","doi":"10.1097/QCO.0000000000001211","DOIUrl":"10.1097/QCO.0000000000001211","url":null,"abstract":"Purpose of review: Novel vaccines for dengue and chikungunya viruses offer new prevention options against two globally important arboviral diseases. This review summarizes recent developments in vaccine licensure, implementation, real-world experience and research priorities, with emphasis on implications for both endemic populations and travelers.Recent findings: Of the three live-attenuated dengue vaccines licensed to date, TAK-003 is authorized in >40 countries and Butantan-DV in Brazil, while manufacturing of CYD-TDV is discontinued. Long-term and postmarketing data continue to refine understanding of serotype-specific protection, waning immunity, and rare adverse events.For chikungunya, two single-dose vaccines are licensed-a live-attenuated vaccine (VLA1553) and virus-like particle vaccine (PXVX0317). Uptake is guided by emerging safety and effectiveness data, with each platform offering potential advantages in different settings.Further data on long-term protection, safety, effectiveness, use in vulnerable populations and integration into outbreak management and immunization systems is anticipated.Summary: Dengue and chikungunya vaccines are increasingly being used in immunization programs and pretravel consultations. Further real-world data are needed-particularly for seronegative dengue vaccine recipients and older, immunocompromised or medically at-risk adults. Research priorities include developing single-dose, nonlive dengue vaccines suitable for high-risk groups, understanding long-term chikungunya vaccine performance, and exploring broader flaviviral or pan-arboviral platforms.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"404-414"},"PeriodicalIF":4.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0